BioCryst Pharmaceuticals Inc. (BCRX)

1.70
0.09 5.00
NASDAQ : Health Technology
Prev Close 1.79
Open 1.61
Day Low/High 1.51 / 1.73
52 Wk Low/High 1.76 / 9.95
Volume 3.09M
Avg Volume 1.44M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 210.94M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insider Trading Alert - BDN, MRCY And BCRX Traded By Insiders

Insider Trading Alert - BDN, MRCY And BCRX Traded By Insiders

Stocks with insider trader activity include BDN, MRCY and BCRX

Bullish Two Hundred Day Moving Average Cross - BCRX

Bullish Two Hundred Day Moving Average Cross - BCRX

In trading on Monday, shares of BioCryst Pharmaceuticals, Inc. crossed above their 200 day moving average of $10.97, changing hands as high as $11.17 per share.

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Dyax jumps after HAE data, while analysts defend competitors Shire, BioCryst

Dyax jumps after HAE data, while analysts defend competitors Shire, BioCryst

The shares of drug maker Dyax are surging after the company last night reported data from a Phase 1b clinical trial of its DX-2930 drug, a treatment for hereditary angioedema...

BioCryst (BCRX) Stock Gains Today on Ebola Treatment Contract With U.S. Government

BioCryst (BCRX) Stock Gains Today on Ebola Treatment Contract With U.S. Government

BioCryst (BCRX) share are climbing after the company announced a contract with the U.S. Department of Health and Human Services to develop an Ebola treatment.

BioCryst Awarded BCX4430 Advanced Development Contract

BioCryst Awarded BCX4430 Advanced Development Contract

BARDA Awards NDA Enabling CMC & Non-Clinical Toxicology Studies Contract for BCX4430

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - MKSI, BCRX And CSGS Traded By Insiders

Insider Trading Alert - MKSI, BCRX And CSGS Traded By Insiders

Stocks with insider trader activity include MKSI, BCRX and CSGS

Insider Trading Alert - BCRX, MHFI And MMP Traded By Insiders

Insider Trading Alert - BCRX, MHFI And MMP Traded By Insiders

Stocks with insider trader activity include BCRX, MHFI and MMP

Insider Trading Alert - BCRX, MHFI And MMP Traded By Insiders

Insider Trading Alert - BCRX, MHFI And MMP Traded By Insiders

Stocks with insider trader activity include BCRX, MHFI and MMP

'Mad Money' Lightning Round: Buy Enbridge Energy Partners

'Mad Money' Lightning Round: Buy Enbridge Energy Partners

Cramer isn't excited by Yahoo!, would buy more Xcel Energy and likes Cisco over Arris Group.

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Despite the many strides the market has made since 2000, critics are once again calling the Nasdaq overvalued and in 'bubble' territory. Cramer details why they're wrong.

BioCryst Pharmaceuticals Stock Sees Short Interest Move 10% Higher

BioCryst Pharmaceuticals Stock Sees Short Interest Move 10% Higher

The most recent short interest data has been released by the NASDAQ for the 01/30/2015 settlement date, which shows a 1,102,518 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 12,060,331, an increase of 10.06% since 01/15/2015.

First Week of February 20th Options Trading For BioCryst Pharmaceuticals (BCRX)

First Week of February 20th Options Trading For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options become available this week, for the February 20th expiration.

First Week of BCRX September 18th Options Trading

First Week of BCRX September 18th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

TheStreet Quant Rating: D- (Sell)